ClinicalTrials.gg
TerminatedNCT06655818Updated Mar 3, 2025Results posted

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

A Phase 1/2 interventional study of Belantamab Mafodotin and Dostarlimab in Relapsed/Refractory Multiple Myeloma, sponsored by GlaxoSmithKline. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to lack of efficacy

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Mar 2021, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
44th of 49
4 · median 50
Started
2021
with 10 others
Phase 1/2
17 of 49
3 open now
Registered
34th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 44th largest by enrollment, is one of 11 that started in 2021, is one of 17 in phase 1/2, and was the 34th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase. This study is a sub study of the Master protocol (NCT04126200).

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years of age inclusive or older, at the time of signing the .
  • Participants must have or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG.
  • Participants having at least 3 prior lines of prior anti-myeloma treatments including an immunomodulating agent (IMID) a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.
  • Participants with a history of stem cell transplant are eligible for study participation when, transplant was >100 days prior to study enrolment and with no active infection(s).
  • Participants with (ECOG) performance status of 0-1, unless ECOG less than equal to (\<=)2 is due solely to skeletal complications and/or skeletal pain due to MM.
  • Participants with defined as at least one of the following: Serum M-protein greater than equal to (>=)0.5 gram per deciliter (>=5 gram per liter) or Urine M-protein >=200 milligrams (mg) per 24 hours or Serum free light chain (FLC) assay: Involved FLC level >=10 mg per deciliter (>=100 mg per Liter) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Participants who have tested positive for core antibody (HBcAb) can be enrolled if the following criteria are met: Serology result HBcAb+, Hepatitis B surface antigen (HBsAg)-; HBV deoxyribonucleic acid (DNA) undetectable during screening.
  • Participants who are currently receiving physiological doses oral (\<10 mg/day), inhaled steroids or ophthalmological steroids.

Exclusion criteria

Exclusion Criteria:

  • Participants with current corneal epithelial disease except mild punctate keratopathy.
  • Participants with evidence of cardiovascular risk.
  • Participants with known immediate or delayed reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other mAb.
  • Participants with active infection requiring antibiotic, antiviral, or antifungal treatment.
  • Participants with other monoclonal antibodies within 30 days or systemic anti-myeloma therapy within \<14 days.
  • Participants with prior radiotherapy within 2 weeks of start of study therapy.
  • Participants with prior transplant are prohibited.
  • Participants who have received prior Chimeric Antigen T cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.
  • Participants with any major surgery (other than bone-stabilizing surgery) within the last 30 days.
  • Participants with prior treatment with an agent within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is shorter.
  • Participants with >=grade 3 toxicity considered related to prior check-point inhibitors and that led to treatment discontinuation.
  • Participants who have received transfusion of blood products within 2 weeks before the first dose of study drug.
  • Participants must not receive within 30 days prior to first dose of study treatment or whilst receiving belantamab mafodotin +- partner agent in any sub-study arm of the platform trial and for at least 70 days following last study treatment.
  • Participants with presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM.
  • Participants with known (HIV) infection, unless the participant can meet all criteria: a) established anti-retroviral therapy for at least 4 weeks and HIV viral load\<400 copies/milliliter (mL) b) cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts >= 350 cells/microliter (µL) c) No history of Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months in which case the participant would be eligible for CE Phase only.
  • Participants with disease (current or history) or syndrome that required systemic treatment within the past 2 years.
  • Exclusion for a recent (within the past 6 months) history of symptomatic pericarditis.
  • Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, , or drugs).
  • Participants who have received prior therapy with an anti-programmed death-1 (), anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Belantamab mafodotin + Dostarlimab

    Drug: Belantamab Mafodotin · Drug: Dostarlimab

Interventions

  • Belantamab Mafodotin will be administered.

    Also known as: GSK2857916

  • Dostarlimab will be administered.

    Also known as: GSK4057190

06

What researchers measure

Primary outcomes

  1. DE Phase: Number of Participants With Dose Limiting Toxicities (DLT)

    Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as Grade 3-5 febrile neutropenia and thrombocytopenia with bleeding. Non-hematologic criteria, excluding corneal toxicity, comprise Grade 3-5 toxicities, with exceptions for manageable nausea, vomiting, or diarrhea, controlled Grade 3 hypertension, and events linked to disease progression. Tumor lysis syndrome (TLS) of Grade 3 or 4, successfully managed within 7 days without end-organ damage, is considered. Corneal toxicity, assessed by the GSK corneal grading scale at Grade 4, is a DLT. Other organ-specific toxicities, notably liver toxicity meeting GSK stopping criteria, also qualify as DLTs. Severity was graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (version 5.0).

    Time frame: Up to 21 days

  2. DE Phase: Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to 153 weeks

  3. DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline

    Blood samples were collected for the analysis of following hematology parameters: eosinophils, anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, leukocytosis and white blood cell decreased. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

    Time frame: Baseline (Day 1) and up to 153 weeks

  4. DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline

    Blood samples were collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and chronic kidney disease. G1: mild; G2: moderate; G3: severe. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented. The laboratory parameters were graded according to CTCAE version 5.

    Time frame: Baseline (Day 1) and up to 153 weeks

  5. CE Phase: Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed PR or better as the best overall response (i.e., Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Up to 26 weeks

Secondary outcomes

  1. DE Phase: Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed PR or better as the best overall response (i.e., Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Up to 153 weeks

  2. CE Phase: Clinical Benefit Rate (CBR)

    Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.

    Time frame: Up to 153 weeks

  3. DE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)

    Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Up to 153 weeks

  4. CE Phase: Percentage of Participants Achieving SCR, CR, VGPR and PR

    Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Up to 153 weeks

  5. DE Phase: Belantamab Mafodotin Concentrations for Plasma Antibody-Drug Conjugate (ADC)

    Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC) when administered intravenously in combination with dostarlimab.

    Time frame: Predose, end of infusion (EOI), 2, and 24 hours postdose on Cycle 1 Day 1, and at Cycle 1 Day 4, Day 8, Day 22, Predose and EOI on Cycle 2 Day 1, Cycle 4 Day 1, and at end of treatment (approximately 153 weeks)

  6. DE Phase: Belantamab Mafodotin Concentrations for Plasma Total Antibody

    Blood samples were collected for PK analysis of belantamab mafodotin total antibody when administered intravenously in combination with dostarlimab.

    Time frame: Predose, end of infusion (EOI), 2, and 24 hours postdose on Cycle 1 Day 1, and at Cycle 1 Day 4, Day 8, Day 22, Predose and EOI on Cycle 2 Day 1, Cycle 4 Day 1, and at end of treatment (approximately 153 weeks)

  7. DE Phase: Belantamab Mafodotin Concentrations for Plasma Cys-mcMMAF

    Blood samples were collected for PK analysis of belantamab mafodotin cys-mcMMAF when administered intravenously in combination with dostarlimab.

    Time frame: Predose, end of infusion (EOI), 2, and 24 hours postdose on Cycle 1 Day 1, and at Cycle 1 Day 4, Day 8, Day 22, Predose and EOI on Cycle 2 Day 1, Cycle 4 Day 1, and at end of treatment (approximately 153 weeks)

  8. CE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)

    Blood samples were to be collected for PK analysis of Belantamab Mafodotin Antibody-Drug Conjugate (ADC).

    Time frame: Up to 153 weeks

  9. CE Phase: Plasma Concentration of Belantamab Mafodotin Plasma Total Antibody

    Blood samples were to be collected for PK analysis of Belantamab mafodotin plasma total antibody.

    Time frame: Up to 153 weeks

  10. CE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

    Blood samples were to be collected for PK analysis of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

    Time frame: Up to 153 weeks

  11. DE Phase: Dostarlimab Concentration When Administered in Combination With Belantamab Mafodotin

    Blood samples were collected for PK analysis of dostarlimab when administered intravenously in combination with belantamab mafodotin.

    Time frame: Predose and end of infusion (EOI) on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 5 Day 1, and at the end of treatment (approximately 153 weeks)

  12. CE Phase: Dostarlimab Concentration When Administered in Combination With Belantamab Mafodotin

    Blood samples were to be collected for PK analysis of dostarlimab when administered intravenously in combination with belantamab mafodotin.

    Time frame: Up to 153 weeks

  13. DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

    Time frame: Up to 153 weeks

  14. CE Phase: Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to 153 weeks

  15. DE Phase: Number of Participants With Post-baseline Positive ADAs Against Dostarlimab

    Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

    Time frame: Up to 153 weeks

  16. CE Phase: Number of Participants With Post-baseline Positive ADAs Against Dostarlimab

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to 153 weeks

  17. DE Phase: Concentration of ADAs Against Dostarlimab When Administered in Combination With Belantamab Mafodotin

    Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to 153 weeks

  18. CE Phase: Concentration of ADAs Against Dostarlimab When Administered in Combination With Belantamab Mafodotin

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to 153 weeks

  19. DE Phase: Concentration of ADAs Against Belantamab Mafodotin

    Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to 153 weeks

  20. CE Phase: Concentration of ADAs Against Belantamab Mafodotin

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

    Time frame: Up to 153 weeks

  21. DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events of special interest (AESIs) were collected.

    Time frame: Up to 153 weeks

  22. CE Phase: Number of Participants With Adverse Events of Special Interest (AESI)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events of special interest (AESIs) were to be collected.

    Time frame: Up to 153 weeks

  23. DE Phase: Number of Participants With Any Corneal Event by Maximum Grade as Per CTCAE Grade

    The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade.

    Time frame: Up to 153 weeks

  24. CE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade

    The corneal events were to be graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Corneal Events were to be examined.

    Time frame: Up to 153 weeks

  25. CE Phase: Progression-free Survival (PFS)

    PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.

    Time frame: Up to 153 weeks

  26. CE Phase: Duration of Response (DoR)

    DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.

    Time frame: Up to 153 weeks

  27. CE Phase: Time to Response (TTR)

    TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).

    Time frame: Up to 153 weeks

  28. CE Phase: Overall Survival (OS)

    OS is defined as the time from randomization until death due to any cause.

    Time frame: Up to 153 weeks

  29. CE Phase: Number of Participants With AEs and SAEs

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to 153 weeks

  30. CE Phase: Number of Participants With AEs Leading to Discontinuation

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to discontinuation were to be evaluated.

    Time frame: Up to 153 weeks

  31. CE Phase: Number of Participants With Dose Reduction or Delay

    Number of participants with dose reduction or delay were to be evaluated.

    Time frame: Up to 153 weeks

  32. CE Phase: Number of Participants With Clinically Significant Changes in Hematology Lab Parameters

    Blood samples were to be collected for the analysis of following hematology parameters: eosinophils, anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, leukocytosis and white blood cell decreased. The laboratory parameters were to be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

    Time frame: Up to 153 weeks

  33. CE Phase: Number of Participants With Clinically Significant Changes in Clinical Chemistry Lab Parameters

    Blood samples were to be collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and chronic kidney disease. The laboratory parameters were to be graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

    Time frame: Up to 153 weeks

07

Results

Posted Mar 3, 2025

Participant flow

This is a sub study of the master study NCT04126200. This sub study was terminated due to lack of efficacy. The study was planned to include two phases - Dose Escalation (DE) and Cohort Expansion (CE) and no participants from this sub study were enrolled in CE phase as study was early terminated.

Participant flow — Overall Study
Milestone1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Started4
Completed3
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryDE Phase: Number of Participants With Dose Limiting Toxicities (DLT)

Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as Grade 3-5 febrile neutropenia and thrombocytopenia with bleeding. Non-hematologic criteria, excluding corneal toxicity, comprise Grade 3-5 toxicities, with exceptions for manageable nausea, vomiting, or diarrhea, controlled Grade 3 hypertension, and events linked to disease progression. Tumor lysis syndrome (TLS) of Grade 3 or 4, successfully managed within 7 days without end-organ damage, is considered. Corneal toxicity, assessed by the GSK corneal grading scale at Grade 4, is a DLT. Other organ-specific toxicities, notably liver toxicity meeting GSK stopping criteria, also qualify as DLTs. Severity was graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (version 5.0).

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Dose Limiting Toxicities (DLT)
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
DE Phase: Number of Participants With Dose Limiting Toxicities (DLT)1
PrimaryDE Phase: Number of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to 153 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Adverse Events (AEs)
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
DE Phase: Number of Participants With Adverse Events (AEs)4
PrimaryDE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline

Blood samples were collected for the analysis of following hematology parameters: eosinophils, anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, leukocytosis and white blood cell decreased. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

Time frame:
Baseline (Day 1) and up to 153 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Eosinophilia, Increase to Grade 10
Eosinophilia, Increase to Grade 20
Eosinophilia, Increase to Grade 30
Eosinophilia, Increase to Grade 40
Anemia, Increase to Grade 10
Anemia, Increase to Grade 21
Anemia, Increase to Grade 31
Anemia, Increase to Grade 40
Hemoglobin increased, Increase to Grade 10
Hemoglobin increased, Increase to Grade 21
Hemoglobin increased, Increase to Grade 30
Hemoglobin increased, Increase to Grade 40
Lymphocyte count decreased, Increase to Grade 10
Lymphocyte count decreased, Increase to Grade 20
Lymphocyte count decreased, Increase to Grade 30
Lymphocyte count decreased, Increase to Grade 42
Lymphocyte count increased, Increase to Grade 10
Lymphocyte count increased, Increase to Grade 21
Lymphocyte count increased, Increase to Grade 30
Lymphocyte count increased, Increase to Grade 40
Neutrophil count decreased, Increase to Grade 10
Neutrophil count decreased, Increase to Grade 21
Neutrophil count decreased, Increase to Grade 31
Neutrophil count decreased, Increase to Grade 41
Platelet count decreased, Increase to Grade 11
Platelet count decreased, Increase to Grade 20
Platelet count decreased, Increase to Grade 32
Platelet count decreased, Increase to Grade 40
Leukocytosis, Increase to Grade 10
Leukocytosis, Increase to Grade 20
Leukocytosis, Increase to Grade 30
Leukocytosis, Increase to Grade 40
White blood cell decreased, Increase to Grade 10
White blood cell decreased, Increase to Grade 20
White blood cell decreased, Increase to Grade 30
White blood cell decreased, Increase to Grade 41
PrimaryDE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline

Blood samples were collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and chronic kidney disease. G1: mild; G2: moderate; G3: severe. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented. The laboratory parameters were graded according to CTCAE version 5.

Time frame:
Baseline (Day 1) and up to 153 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Hypoglycemia, Increase to Grade 10
Hypoglycemia, Increase to Grade 20
Hypoglycemia, Increase to Grade 30
Hypoalbuminemia, Increase to Grade 10
Hypoalbuminemia, Increase to Grade 22
Hypoalbuminemia, Increase to Grade 30
Alkaline phosphatase increased, Increase to Grade 10
Alkaline phosphatase increased, Increase to Grade 20
Alkaline phosphatase increased, Increase to Grade 30
Alanine aminotransferase increased, Increase to Grade 12
Alanine aminotransferase increased, Increase to Grade 21
Alanine aminotransferase increased, Increase to Grade 30
Aspartate aminotransferase increased, Increase to Grade 12
Aspartate aminotransferase increased, Increase to Grade 20
Aspartate aminotransferase increased, Increase to Grade 31
Blood bilirubin increased, Increase to Grade 10
Blood bilirubin increased, Increase to Grade 21
Blood bilirubin increased, Increase to Grade 30
CPK increased, Increase to Grade 11
CPK increased, Increase to Grade 20
CPK increased, Increase to Grade 30
Creatinine increased, Increase to Grade 12
Creatinine increased, Increase to Grade 20
Creatinine increased, Increase to Grade 30
GGT increased, Increase to Grade 11
GGT increased, Increase to Grade 20
GGT increased, Increase to Grade 30
Hyperkalemia, Increase to Grade 10
Hyperkalemia, Increase to Grade 20
Hyperkalemia, Increase to Grade 30
Blood lactate dehydrogenase increased, Increase to Grade 14
Blood lactate dehydrogenase increased, Increase to Grade 20
Blood lactate dehydrogenase increased, Increase to Grade 30
Hypermagnesemia, Increase to Grade 11
Hypermagnesemia, Increase to Grade 20
Hypermagnesemia, Increase to Grade 30
Hypomagnesemia, Increase to Grade 10
Hypomagnesemia, Increase to Grade 20
Hypomagnesemia, Increase to Grade 30
Hypernatremia, Increase to Grade 10
Hypernatremia, Increase to Grade 20
Hypernatremia, Increase to Grade 30
Hypercalcemia, Increase to Grade 11
Hypercalcemia, Increase to Grade 20
Hypercalcemia, Increase to Grade 30
Hypocalcemia, Increase to Grade 10
Hypocalcemia, Increase to Grade 20
Hypocalcemia, Increase to Grade 30
Chronic Kidney Disease, Increase to Grade 10
Chronic Kidney Disease, Increase to Grade 20
Chronic Kidney Disease, Increase to Grade 30
PrimaryCE Phase: Overall Response Rate (ORR)

Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed PR or better as the best overall response (i.e., Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Up to 26 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Overall Response Rate (ORR)

Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed PR or better as the best overall response (i.e., Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Up to 153 weeks
Reported as:
Number · Percentage of participants
DE Phase: Overall Response Rate (ORR)
Percentage of participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
DE Phase: Overall Response Rate (ORR)25 (0.6 to 80.6)
SecondaryCE Phase: Clinical Benefit Rate (CBR)

Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)

Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Up to 153 weeks
Reported as:
Number · Percentage of participants
DE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)
Percentage of participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Stringent Complete Response (sCR)0
Complete Response (CR)0
Very Good Partial Response (VGPR)25
Partial Response (PR)0
SecondaryCE Phase: Percentage of Participants Achieving SCR, CR, VGPR and PR

Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Belantamab Mafodotin Concentrations for Plasma Antibody-Drug Conjugate (ADC)

Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC) when administered intravenously in combination with dostarlimab.

Time frame:
Predose, end of infusion (EOI), 2, and 24 hours postdose on Cycle 1 Day 1, and at Cycle 1 Day 4, Day 8, Day 22, Predose and EOI on Cycle 2 Day 1, Cycle 4 Day 1, and at end of treatment (approximately 153 weeks)
Reported as:
Median · Nanogram/ millilitre (ng/mL)
DE Phase: Belantamab Mafodotin Concentrations for Plasma Antibody-Drug Conjugate (ADC)
Nanogram/ millilitre (ng/mL)1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
CYCLE 1 DAY 1, PRE-DOSE0.0 (0 to 0)
CYCLE 1 DAY 1, END OF INFUSION25300.0 (15800 to 32300)
CYCLE 1 DAY 1, 2 HOURS26450.0 (17900 to 31100)
CYCLE 1 DAY 1, 24 HOURS20400.0 (8030 to 22200)
CYCLE 1 DAY 49110.0 (5100 to 14500)
CYCLE 1 DAY 84830.0 (2040 to 6990)
CYCLE 1 DAY 220.0
CYCLE 2 DAY 1, PRE-DOSE1295.0 (1050 to 1540)
CYCLE 2 DAY 1, END OF INFUSION41950.0 (35000 to 48900)
CYCLE 4 DAY 1, PRE-DOSE0.0
CYCLE 4 DAY 1, END OF INFUSION27600.0
END OF TREATMENT0.0
SecondaryDE Phase: Belantamab Mafodotin Concentrations for Plasma Total Antibody

Blood samples were collected for PK analysis of belantamab mafodotin total antibody when administered intravenously in combination with dostarlimab.

Time frame:
Predose, end of infusion (EOI), 2, and 24 hours postdose on Cycle 1 Day 1, and at Cycle 1 Day 4, Day 8, Day 22, Predose and EOI on Cycle 2 Day 1, Cycle 4 Day 1, and at end of treatment (approximately 153 weeks)
Reported as:
Median · ng/mL
DE Phase: Belantamab Mafodotin Concentrations for Plasma Total Antibody
ng/mL1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
CYCLE 1 DAY 1, PRE-DOSE0.0 (0 to 0)
CYCLE 1 DAY 1, END OF INFUSION31000.0 (20700 to 34500)
CYCLE 1 DAY 1, 2 HOURS32400.0 (19800 to 41100)
CYCLE 1 DAY 1, 24 HOURS21400.0 (12600 to 23600)
CYCLE 1 DAY 415000.0 (7810 to 17800)
CYCLE 1 DAY 88235.0 (4530 to 12000)
CYCLE 1 DAY 221140.0
CYCLE 2 DAY 1, PRE-DOSE3625.0 (3480 to 3770)
CYCLE 2 DAY 1, END OF INFUSION45350.0 (35500 to 55200)
CYCLE 4 DAY 1, PRE-DOSE2800.0
CYCLE 4 DAY 1, END OF INFUSION48900.0
END OF TREATMENT628.0
SecondaryDE Phase: Belantamab Mafodotin Concentrations for Plasma Cys-mcMMAF

Blood samples were collected for PK analysis of belantamab mafodotin cys-mcMMAF when administered intravenously in combination with dostarlimab.

Time frame:
Predose, end of infusion (EOI), 2, and 24 hours postdose on Cycle 1 Day 1, and at Cycle 1 Day 4, Day 8, Day 22, Predose and EOI on Cycle 2 Day 1, Cycle 4 Day 1, and at end of treatment (approximately 153 weeks)
Reported as:
Median · ng/mL
DE Phase: Belantamab Mafodotin Concentrations for Plasma Cys-mcMMAF
ng/mL1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
CYCLE 1 DAY 1, PRE-DOSE0.00 (0.0 to 0.0)
CYCLE 1 DAY 1, END OF INFUSION218.00 (147.0 to 447.0)
CYCLE 1 DAY 1, 2 HOURS376.00 (231.0 to 556.0)
CYCLE 1 DAY 1, 24 HOURS750.00 (547.0 to 1670.0)
CYCLE 1 DAY 4549.50 (218.0 to 1780.0)
CYCLE 1 DAY 8170.90 (67.1 to 264.0)
CYCLE 1 DAY 220.00
CYCLE 2 DAY 1, PRE-DOSE0.00 (0.0 to 0.0)
CYCLE 2 DAY 1, END OF INFUSION555.00 (394.0 to 716.0)
CYCLE 4 DAY 1, PRE-DOSE0.00
CYCLE 4 DAY 1, END OF INFUSION469.00
END OF TREATMENT0.00
SecondaryCE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)

Blood samples were to be collected for PK analysis of Belantamab Mafodotin Antibody-Drug Conjugate (ADC).

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Plasma Concentration of Belantamab Mafodotin Plasma Total Antibody

Blood samples were to be collected for PK analysis of Belantamab mafodotin plasma total antibody.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

Blood samples were to be collected for PK analysis of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Dostarlimab Concentration When Administered in Combination With Belantamab Mafodotin

Blood samples were collected for PK analysis of dostarlimab when administered intravenously in combination with belantamab mafodotin.

Time frame:
Predose and end of infusion (EOI) on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 5 Day 1, and at the end of treatment (approximately 153 weeks)
Reported as:
Median · ng/mL
DE Phase: Dostarlimab Concentration When Administered in Combination With Belantamab Mafodotin
ng/mL1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
CYCLE 1 DAY 1, PRE-DOSE0.0 (0 to 203000)
CYCLE 1 DAY 1, END OF INFUSION52500.0 (0 to 124000)
CYCLE 2 DAY 1, PRE-DOSE43550.0 (23900 to 63200)
CYCLE 2 DAY 1, END OF INFUSION224000.0 (149000 to 299000)
CYCLE 5 DAY 1, PRE-DOSE532.0
CYCLE 5 DAY 1, END OF INFUSION312000.0
END OF TREATMENT35750.0 (12200 to 59300)
SecondaryCE Phase: Dostarlimab Concentration When Administered in Combination With Belantamab Mafodotin

Blood samples were to be collected for PK analysis of dostarlimab when administered intravenously in combination with belantamab mafodotin.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

Time frame:
Up to 153 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin1
SecondaryCE Phase: Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Number of Participants With Post-baseline Positive ADAs Against Dostarlimab

Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

Time frame:
Up to 153 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Post-baseline Positive ADAs Against Dostarlimab
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
DE Phase: Number of Participants With Post-baseline Positive ADAs Against Dostarlimab0
SecondaryCE Phase: Number of Participants With Post-baseline Positive ADAs Against Dostarlimab

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Concentration of ADAs Against Dostarlimab When Administered in Combination With Belantamab Mafodotin

Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Concentration of ADAs Against Dostarlimab When Administered in Combination With Belantamab Mafodotin

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Concentration of ADAs Against Belantamab Mafodotin

Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to 153 weeks
Reported as:
Mean · ng/mL
DE Phase: Concentration of ADAs Against Belantamab Mafodotin
ng/mL1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
DE Phase: Concentration of ADAs Against Belantamab MafodotinNA ± NA
SecondaryCE Phase: Concentration of ADAs Against Belantamab Mafodotin

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Number of Participants With Adverse Events of Special Interest (AESI)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events of special interest (AESIs) were collected.

Time frame:
Up to 153 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)3
SecondaryCE Phase: Number of Participants With Adverse Events of Special Interest (AESI)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events of special interest (AESIs) were to be collected.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryDE Phase: Number of Participants With Any Corneal Event by Maximum Grade as Per CTCAE Grade

The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade.

Time frame:
Up to 153 weeks
Reported as:
Count of participants · Participants
DE Phase: Number of Participants With Any Corneal Event by Maximum Grade as Per CTCAE Grade
Participants1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Grade 11
Grade 20
Grade 30
SecondaryCE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade

The corneal events were to be graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Corneal Events were to be examined.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Progression-free Survival (PFS)

PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Duration of Response (DoR)

DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Time to Response (TTR)

TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Overall Survival (OS)

OS is defined as the time from randomization until death due to any cause.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With AEs and SAEs

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With AEs Leading to Discontinuation

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to discontinuation were to be evaluated.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With Dose Reduction or Delay

Number of participants with dose reduction or delay were to be evaluated.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With Clinically Significant Changes in Hematology Lab Parameters

Blood samples were to be collected for the analysis of following hematology parameters: eosinophils, anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, leukocytosis and white blood cell decreased. The laboratory parameters were to be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

SecondaryCE Phase: Number of Participants With Clinically Significant Changes in Clinical Chemistry Lab Parameters

Blood samples were to be collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and chronic kidney disease. The laboratory parameters were to be graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.

Time frame:
Up to 153 weeks

No measurements were reported for this outcome.

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected maximum up to 153 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab2/4 (50%)2/4 (50%)4/4 (100%)
Most frequent serious events
Most frequent serious events
Event1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
PyrexiaGeneral disorders1/4
HypercalcaemiaMetabolism and nutrition disorders1/4
Most frequent other events
Showing 10 of 16
Most frequent other events
Event1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
ThrombocytopeniaBlood and lymphatic system disorders2/4
Vision blurredEye disorders2/4
Productive coughRespiratory, thoracic and mediastinal disorders2/4
Dry eyeEye disorders1/4
Eye irritationEye disorders1/4
Foreign body sensation in eyesEye disorders1/4
DiarrhoeaGastrointestinal disorders1/4
PainGeneral disorders1/4
PyrexiaGeneral disorders1/4
Alanine aminotransferase increasedInvestigations1/4

Baseline characteristics

Age, Continuous
Age, Continuous(YEAR)1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Mean70.0 ± 9.83
Sex/Gender, Customized
Sex/Gender, Customized(Participants)1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Males and Females4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
Others4
08

Study locations

3 sites
  • GSK Investigational Site
    Lille, France
  • GSK Investigational Site
    Seoul, Korea, Republic of
  • GSK Investigational Site
    Ulsan, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Feb 2024, 35 months.

Results were first posted in Mar 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 23, 2024
StartActual
Mar 9, 2021
Primary completionActual
Feb 14, 2024
CompletionActual
Feb 14, 2024
Results first posted
Mar 3, 2025
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06655818
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Mar 9, 2021
Primary completion
Feb 14, 2024
Completion
Feb 14, 2024
Results posted
Mar 3, 2025
Last update
Mar 3, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab mafodotin · Dostarlimab

Start the discussion